Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review
Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with immune thrombocytopenia (ITP). We conducted a meta-analysis of primary ITP treatment with the TPO-RA Romiplostim, Eltrombopag and Avatr...
Uloženo v:
| Vydáno v: | Platelets (Edinburgh) Ročník 32; číslo 2; s. 216 - 226 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Taylor & Francis
17.02.2021
Taylor & Francis Group |
| Témata: | |
| ISSN: | 0953-7104, 1369-1635, 1369-1635 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with immune thrombocytopenia (ITP). We conducted a meta-analysis of primary ITP treatment with the TPO-RA Romiplostim, Eltrombopag and Avatrombopag, including additional studies and relevant endpoints. We searched MEDLINE, EMBASE and CENTRAL for randomized clinical trials (RCTs) and cohort studies on TPO-RA in ITP published until December 31, 2018. The primary endpoints were: risk ratio (RR) of treatment failure and bleeding of WHO grade ≥2; rate of remission after discontinuation of treatment. The principal safety outcome was RR and incidence of thrombotic events and liver damage. From 1044 identified records we selected 16 RCTs and 19 cohort studies. RCTs included 909 patients assigned to TPO-RA and 427 to the control arm. Treatment failure was observed in 21% TPO-RA-treated patients and 47% control arm patients (RR = 0.42, 95% CI 0.33-0.53) in RCTs during a median follow-up of 13 weeks, and in 29% TPO-RA-treated patients in cohort studies, during a median follow-up of 69 weeks. The incidence of remission after TPO discontinuation was 18% (5-36%). RR of WHO grade ≥2 bleeding was 0.58 (0.38-0.86) in TPO-RA-treated patients, compared to control arm patients. Adverse events were rare and not significantly different in the two groups of patients. All-cause mortality was significantly lower with TPO-RA (RR 0.21, 95% CI, 0.06-0.68). In conclusion, TPO-RA are effective and safe in patients with ITP, even in the long term. |
|---|---|
| AbstractList | Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with immune thrombocytopenia (ITP). We conducted a meta-analysis of primary ITP treatment with the TPO-RA Romiplostim, Eltrombopag and Avatrombopag, including additional studies and relevant endpoints. We searched MEDLINE, EMBASE and CENTRAL for randomized clinical trials (RCTs) and cohort studies on TPO-RA in ITP published until December 31, 2018. The primary endpoints were: risk ratio (RR) of treatment failure and bleeding of WHO grade ≥2; rate of remission after discontinuation of treatment. The principal safety outcome was RR and incidence of thrombotic events and liver damage. From 1044 identified records we selected 16 RCTs and 19 cohort studies. RCTs included 909 patients assigned to TPO-RA and 427 to the control arm. Treatment failure was observed in 21% TPO-RA-treated patients and 47% control arm patients (RR = 0.42, 95% CI 0.33–0.53) in RCTs during a median follow-up of 13 weeks, and in 29% TPO-RA-treated patients in cohort studies, during a median follow-up of 69 weeks. The incidence of remission after TPO discontinuation was 18% (5–36%). RR of WHO grade ≥2 bleeding was 0.58 (0.38–0.86) in TPO-RA-treated patients, compared to control arm patients. Adverse events were rare and not significantly different in the two groups of patients. All-cause mortality was significantly lower with TPO-RA (RR 0.21, 95% CI, 0.06–0.68). In conclusion, TPO-RA are effective and safe in patients with ITP, even in the long term. Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with immune thrombocytopenia (ITP). We conducted a meta-analysis of primary ITP treatment with the TPO-RA Romiplostim, Eltrombopag and Avatrombopag, including additional studies and relevant endpoints. We searched MEDLINE, EMBASE and CENTRAL for randomized clinical trials (RCTs) and cohort studies on TPO-RA in ITP published until December 31, 2018. The primary endpoints were: risk ratio (RR) of treatment failure and bleeding of WHO grade ≥2; rate of remission after discontinuation of treatment. The principal safety outcome was RR and incidence of thrombotic events and liver damage. From 1044 identified records we selected 16 RCTs and 19 cohort studies. RCTs included 909 patients assigned to TPO-RA and 427 to the control arm. Treatment failure was observed in 21% TPO-RA-treated patients and 47% control arm patients (RR = 0.42, 95% CI 0.33-0.53) in RCTs during a median follow-up of 13 weeks, and in 29% TPO-RA-treated patients in cohort studies, during a median follow-up of 69 weeks. The incidence of remission after TPO discontinuation was 18% (5-36%). RR of WHO grade ≥2 bleeding was 0.58 (0.38-0.86) in TPO-RA-treated patients, compared to control arm patients. Adverse events were rare and not significantly different in the two groups of patients. All-cause mortality was significantly lower with TPO-RA (RR 0.21, 95% CI, 0.06-0.68). In conclusion, TPO-RA are effective and safe in patients with ITP, even in the long term.Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with immune thrombocytopenia (ITP). We conducted a meta-analysis of primary ITP treatment with the TPO-RA Romiplostim, Eltrombopag and Avatrombopag, including additional studies and relevant endpoints. We searched MEDLINE, EMBASE and CENTRAL for randomized clinical trials (RCTs) and cohort studies on TPO-RA in ITP published until December 31, 2018. The primary endpoints were: risk ratio (RR) of treatment failure and bleeding of WHO grade ≥2; rate of remission after discontinuation of treatment. The principal safety outcome was RR and incidence of thrombotic events and liver damage. From 1044 identified records we selected 16 RCTs and 19 cohort studies. RCTs included 909 patients assigned to TPO-RA and 427 to the control arm. Treatment failure was observed in 21% TPO-RA-treated patients and 47% control arm patients (RR = 0.42, 95% CI 0.33-0.53) in RCTs during a median follow-up of 13 weeks, and in 29% TPO-RA-treated patients in cohort studies, during a median follow-up of 69 weeks. The incidence of remission after TPO discontinuation was 18% (5-36%). RR of WHO grade ≥2 bleeding was 0.58 (0.38-0.86) in TPO-RA-treated patients, compared to control arm patients. Adverse events were rare and not significantly different in the two groups of patients. All-cause mortality was significantly lower with TPO-RA (RR 0.21, 95% CI, 0.06-0.68). In conclusion, TPO-RA are effective and safe in patients with ITP, even in the long term. |
| Author | Casazza, Giovanni Birocchi, Simone Podda, Gian Marco Manzoni, Marco Cattaneo, Marco |
| Author_xml | – sequence: 1 givenname: Simone surname: Birocchi fullname: Birocchi, Simone organization: Università degli Studi di Milano – sequence: 2 givenname: Gian Marco orcidid: 0000-0002-1791-8905 surname: Podda fullname: Podda, Gian Marco email: gmpodda@gmail.com organization: Università degli Studi di Milano – sequence: 3 givenname: Marco surname: Manzoni fullname: Manzoni, Marco organization: Università degli Studi di Milano – sequence: 4 givenname: Giovanni surname: Casazza fullname: Casazza, Giovanni organization: Università degli Studi di Milano – sequence: 5 givenname: Marco surname: Cattaneo fullname: Cattaneo, Marco organization: Università degli Studi di Milano |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32281449$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUUtv1DAQtlAR3RZ-AshHLil-JWvDBVQVqFSJSzlbE2fSukrsxfZSReLH4-3ucuAAp9HMfI_RfGfkJMSAhLzm7IIzzd4x08o1Z-pCMFFHa9XyTj8jKy470_BOtidktcM0O9ApOcv5gTGuWde-IKdSCM2VMivy6_Y-xbmPm-ix-EATOtyUmCjcxeBzyXSsTblHWhJCmTEUGke6SX6GtFA_z9tQd3sRt5S4weDhPQU6Y4EGAkxL9plCGGhecsEZinfV5qfHx5fk-QhTxleHek6-f766vfza3Hz7cn356aZxSorSiEEyrTQazphhUiuBTo2tGdt-GIWBuu5ZK4zqlHISwQyddlDxa0TmWCfPyfVed4jwYA-32wjePg1iurOQ6lkTWnACh_Vai6qvepB926ORusdedoIZVbXe7rU2Kf7YYi529tnhNEHAuM1WSG0E55rvbN8coNt-xuGP8fH7FfBhD3Ap5pxwtM6X-p8YSgI_Wc7sLmt7zNrusraHrCu7_Yt9NPgf7-Oe50PNdobHmKbBFlimmMYEwfls5b8lfgMxksG5 |
| CitedBy_id | crossref_primary_10_1111_bjh_19800 crossref_primary_10_1182_blood_2023020243 crossref_primary_10_2147_JBM_S259101 crossref_primary_10_3389_fonc_2021_680411 crossref_primary_10_1182_blood_2024025067 crossref_primary_10_1007_s00277_023_05114_8 crossref_primary_10_3892_br_2024_1732 crossref_primary_10_1111_bjh_19761 crossref_primary_10_2147_RMHP_S417553 crossref_primary_10_1080_14712598_2021_1960979 crossref_primary_10_1111_ejh_14154 crossref_primary_10_1007_s11739_020_02553_3 crossref_primary_10_1186_s13045_023_01401_z crossref_primary_10_2147_PPA_S505337 crossref_primary_10_1016_j_phrs_2025_107803 crossref_primary_10_1007_s11095_022_03304_z crossref_primary_10_1182_blood_2021010968 crossref_primary_10_1016_j_ijpharm_2025_126123 crossref_primary_10_1002_rai2_70000 crossref_primary_10_17650_1818_8346_2024_19_2_109_117 crossref_primary_10_1002_jha2_70134 crossref_primary_10_1080_07853890_2023_2224044 crossref_primary_10_1111_bjh_19161 crossref_primary_10_1016_j_ejim_2022_11_022 crossref_primary_10_1002_jha2_70010 crossref_primary_10_1080_14656566_2022_2082283 crossref_primary_10_3390_jmahp13020011 crossref_primary_10_1080_17474086_2021_2009337 crossref_primary_10_1177_20406207231172831 crossref_primary_10_1016_j_thromres_2025_109450 |
| Cites_doi | 10.1016/S0140-6736(08)60203-2 10.1016/j.exphem.2004.09.006 10.1007/s00277-011-1172-9 10.1159/000381657 10.1007/s12185-014-1533-y 10.1016/S0140-6736(16)00279-8 10.1111/bjh.12260 10.1111/bjh.12169 10.1182/bloodadvances.2019000966 10.1111/bjh.13827 10.1007/s12185-011-0886-8 10.1038/srep39003 10.1007/978-1-4419-7073-2_17 10.1182/blood-2012-07-442392 10.1002/14651858.CD008235.pub2 10.1007/s12185-012-1065-2 10.1007/s12185-013-1439-0 10.1111/ejh.12807 10.1111/bjh.15573 10.1111/j.1365-2141.2008.07464.x 10.1080/14656566.2017.1373091 10.1056/NEJMoa1002625 10.1002/pbc.25136 10.1182/blood-2008-04-150078 10.1111/j.1365-2141.2006.06339.x 10.1111/jcpt.12156 10.1056/NEJMoa054626 10.1182/blood-2010-10-313908 10.1016/j.lpm.2014.01.010 10.1016/S0140-6736(15)61107-2 10.1182/blood-2012-12-467068 10.1182/blood-2017-09-742353 10.1182/blood-2009-01-129155 10.1056/NEJMoa073275 10.1182/blood-2014-01-549360 10.1182/blood-2004-03-1168 10.1016/j.exphem.2009.06.011 10.1056/NEJMoa030254 10.1182/blood.V98.12.3241 10.1182/blood-2008-07-162503 10.1111/j.1538-7836.2012.04695.x 10.1182/blood-2013-07-514398 10.5045/br.2015.50.1.19 10.1016/j.jclinepi.2009.06.006 10.1016/S0140-6736(10)60959-2 10.1111/bjh.12766 10.1182/blood-2003-08-2672 10.1002/ajh.23163 10.1093/ajcp/56.1.24 10.1111/bjh.14380 10.1016/j.jval.2010.10.017 10.1016/j.cyto.2003.05.001 10.1016/S0140-6736(09)60402-5 |
| ContentType | Journal Article |
| Copyright | 2020 Taylor & Francis Group, LLC 2020 |
| Copyright_xml | – notice: 2020 Taylor & Francis Group, LLC 2020 |
| DBID | AAYXX CITATION NPM 7X8 DOA |
| DOI | 10.1080/09537104.2020.1745168 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1369-1635 |
| EndPage | 226 |
| ExternalDocumentID | oai_doaj_org_article_ac2ed7782f594ba3b5be938beb362094 32281449 10_1080_09537104_2020_1745168 1745168 |
| Genre | Systematic Review Journal Article |
| GroupedDBID | --- 00X 03L 0YH 123 29O 36B 4.4 AAGDL AALUX AAMIU AAPUL AAQRR ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLKL ABUPF ABWVI ABXYU ACENM ACGEJ ACGFS ACUHS ADCVX ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AFRVT AGDLA AGFJD AGRBW AGYJP AIJEM AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE AQTUD BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO DU5 EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- RNANH RVRKI SV3 TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TUS UEQFS V1S ~1N AAYXX CITATION ADYSH NPM 7X8 GROUPED_DOAJ |
| ID | FETCH-LOGICAL-c432t-2d30848e9100903842ec4f59f5bdf29ad30b05294644c3ea9d68ca8e97ee0c063 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 37 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000559818200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0953-7104 1369-1635 |
| IngestDate | Fri Oct 03 12:29:37 EDT 2025 Thu Sep 04 18:46:16 EDT 2025 Thu Apr 03 06:56:33 EDT 2025 Tue Nov 18 20:31:56 EST 2025 Sat Nov 29 06:10:55 EST 2025 Mon Oct 20 23:48:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | ITP meta-analysis TPO-RA |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c432t-2d30848e9100903842ec4f59f5bdf29ad30b05294644c3ea9d68ca8e97ee0c063 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-1791-8905 |
| OpenAccessLink | https://doaj.org/article/ac2ed7782f594ba3b5be938beb362094 |
| PMID | 32281449 |
| PQID | 2389211816 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ac2ed7782f594ba3b5be938beb362094 informaworld_taylorfrancis_310_1080_09537104_2020_1745168 pubmed_primary_32281449 proquest_miscellaneous_2389211816 crossref_citationtrail_10_1080_09537104_2020_1745168 crossref_primary_10_1080_09537104_2020_1745168 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-17 |
| PublicationDateYYYYMMDD | 2021-02-17 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Platelets (Edinburgh) |
| PublicationTitleAlternate | Platelets |
| PublicationYear | 2021 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | cit0033 cit0034 cit0031 cit0032 cit0030 cit0039 cit0037 cit0038 cit0035 cit0036 cit0022 cit0023 cit0020 cit0021 cit0028 cit0029 cit0026 cit0027 cit0024 cit0025 cit0011 cit0055 cit0012 cit0053 cit0010 cit0054 cit0051 cit0052 cit0050 cit0019 cit0017 cit0018 cit0015 cit0016 cit0013 cit0014 cit0044 cit0001 cit0045 cit0042 cit0043 cit0040 cit0041 cit0008 cit0009 cit0006 cit0007 cit0004 cit0048 cit0005 cit0049 cit0002 cit0046 cit0003 cit0047 |
| References_xml | – ident: cit0017 doi: 10.1016/S0140-6736(08)60203-2 – ident: cit0011 doi: 10.1016/j.exphem.2004.09.006 – ident: cit0040 doi: 10.1007/s00277-011-1172-9 – ident: cit0051 doi: 10.1159/000381657 – ident: cit0048 doi: 10.1007/s12185-014-1533-y – ident: cit0047 doi: 10.1016/S0140-6736(16)00279-8 – ident: cit0054 doi: 10.1111/bjh.12260 – ident: cit0027 doi: 10.1111/bjh.12169 – ident: cit0007 doi: 10.1182/bloodadvances.2019000966 – ident: cit0019 doi: 10.1111/bjh.13827 – ident: cit0046 doi: 10.1007/s12185-011-0886-8 – ident: cit0034 doi: 10.1038/srep39003 – ident: cit0010 doi: 10.1007/978-1-4419-7073-2_17 – ident: cit0037 doi: 10.1182/blood-2012-07-442392 – ident: cit0035 doi: 10.1002/14651858.CD008235.pub2 – ident: cit0049 doi: 10.1007/s12185-012-1065-2 – ident: cit0021 doi: 10.1007/s12185-013-1439-0 – ident: cit0055 doi: 10.1111/ejh.12807 – ident: cit0045 doi: 10.1111/bjh.15573 – ident: cit0031 doi: 10.1111/j.1365-2141.2008.07464.x – ident: cit0036 doi: 10.1080/14656566.2017.1373091 – ident: cit0018 doi: 10.1056/NEJMoa1002625 – ident: cit0043 doi: 10.1002/pbc.25136 – ident: cit0020 doi: 10.1182/blood-2008-04-150078 – ident: cit0015 doi: 10.1111/j.1365-2141.2006.06339.x – ident: cit0022 doi: 10.1111/jcpt.12156 – ident: cit0016 doi: 10.1056/NEJMoa054626 – ident: cit0039 doi: 10.1182/blood-2010-10-313908 – ident: cit0002 doi: 10.1016/j.lpm.2014.01.010 – ident: cit0044 doi: 10.1016/S0140-6736(15)61107-2 – ident: cit0008 doi: 10.1182/blood-2012-12-467068 – ident: cit0006 doi: 10.1182/blood-2017-09-742353 – ident: cit0014 doi: 10.1182/blood-2009-01-129155 – ident: cit0041 doi: 10.1056/NEJMoa073275 – ident: cit0050 doi: 10.1182/blood-2014-01-549360 – ident: cit0005 doi: 10.1182/blood-2004-03-1168 – ident: cit0012 doi: 10.1016/j.exphem.2009.06.011 – ident: cit0004 doi: 10.1056/NEJMoa030254 – ident: cit0013 doi: 10.1182/blood.V98.12.3241 – ident: cit0001 doi: 10.1182/blood-2008-07-162503 – ident: cit0028 doi: 10.1111/j.1538-7836.2012.04695.x – ident: cit0030 doi: 10.1182/blood-2013-07-514398 – ident: cit0029 doi: 10.5045/br.2015.50.1.19 – ident: cit0042 doi: 10.1016/j.jclinepi.2009.06.006 – ident: cit0026 doi: 10.1016/S0140-6736(10)60959-2 – ident: cit0023 doi: 10.1111/bjh.12766 – ident: cit0003 doi: 10.1182/blood-2003-08-2672 – ident: cit0033 doi: 10.1002/ajh.23163 – ident: cit0038 doi: 10.1093/ajcp/56.1.24 – ident: cit0024 doi: 10.1056/NEJMoa073275 – ident: cit0052 doi: 10.1111/bjh.14380 – ident: cit0032 doi: 10.1016/j.jval.2010.10.017 – ident: cit0009 doi: 10.1016/j.cyto.2003.05.001 – ident: cit0053 doi: 10.1182/blood-2008-04-150078 – ident: cit0025 doi: 10.1016/S0140-6736(09)60402-5 |
| SSID | ssj0018065 |
| Score | 2.436671 |
| SecondaryResourceType | review_article |
| Snippet | Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients... |
| SourceID | doaj proquest pubmed crossref informaworld |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 216 |
| SubjectTerms | ITP meta-analysis TPO-RA |
| SummonAdditionalLinks | – databaseName: Taylor & Francis Journals Complete dbid: TFW link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9xADB4h1AOXlgJtF1pkJNRb2iWZZJPeKGLFASEO25bbaB4OXYlNVptQCak_HnsySWklxKFcN4-dcTzjz2P7sxCH1pARzNFEiZMyInvtIu2Y9zbLCMxi6aSP4H8_n1xc5FdXxWXIJmxCWiX70GVHFOH3al7c2jR9Rtxnpkgjw8gnIvGYM3LSo4zLfcn0cw-D2fTHEEfgsGHHtpdw1qHsa3gee8tf1smT-P9DYfo4EPUGafrqGaayKV4GNArHnfq8FmtYbYnt44o88cUdfASfH-oP3rfF79nPVb0w9bKec5k00FaJS_LYQV_XTL_bAI0fCE_CkLwOdQnLjs4C5lyIQte6l9i7lvt2zfUX0LDAVkc6sKMAzQX-8EtDV1uzI75NT2cnZ1Ho3RBZ-gptFLuEmfqR0AifBOUyRivLtChT48q4IH0YGw4ySsJjNkFduCy3mu6fII4t4aY3Yr2qK3wnINWS_CZDAkqt5JLArLDjMkWSW-ZojxoJ2X8zZQOxOffXuFFHPf9pkLJiKasg5ZH4NDwWRPHUA19ZIYabmZjb_1CvrlVY50rbGN2EYBfNVRqdmNQgLQaDhpACudIjUTxUJ9X6c5mya6KikicGcNDrnqJNgCM7usL6tlGEu4qYS4izkXjbKeUwTNqxc_Kai93_-Oc9sRFzLg83wpm8F-vt6hY_iBf2VztvVvt-yd0D7egmOw priority: 102 providerName: Taylor & Francis |
| Title | Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review |
| URI | https://www.tandfonline.com/doi/abs/10.1080/09537104.2020.1745168 https://www.ncbi.nlm.nih.gov/pubmed/32281449 https://www.proquest.com/docview/2389211816 https://doaj.org/article/ac2ed7782f594ba3b5be938beb362094 |
| Volume | 32 |
| WOSCitedRecordID | wos000559818200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1369-1635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0018065 issn: 0953-7104 databaseCode: TFW dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9RADLag4sAF0ZbHUloZCXELbCeTF7e26ooDqjgssLfRvAIrdZPVbopUiR9fOzNZVkjVXnrJYTJJRrYztsf2Z4D31pASLL1JUidlQvraJdox7m2ekzHrayf7CP6Pr8XVVTmbVd-2Wn1xTliABw6E-6St8K4gPVZnlTQ6NZnx9HZDTmAuyDfh3ZesnsGZivEDDhcGlL2Usw3lULvDqNo0xkPkG4ox5_Nkp4yzuqWVevD-_6BL7zdAe0U0eQ7PogWJZ2Hl-_DINwdweNaQ97y4xQ_Y53T2h-WH8Hf6e9UuTLts51zajLS9-SV52ah_tQyZu0b6NpINiJuEc2xrXAYICpxz8QjdCy-xtx332prrz6hx4Tud6Ihogrpx-A8TGkM9zAv4PrmcXnxJYr-FxMpUdIlwKaPre7Ig-PSmlMJbSWSvM-NqUREPx4YDg5JsKJt6Xbm8tJrmF96PLdk6L2GvaRv_GjDTknwdQxTOrOQyvryy4zrzRPjc0b4yAjnQW9kIRs49Ma7V6YBZGtmkmE0qsmkEHzePRVLseuCcmbmZzGDa_QCJmIoipnaJ2AiqbVFQXX-WUofGJyrdsYB3g9wo-nE5GqMb396sFdlKleCy33wEr4JAbZZJu2xJnm715iGWfwRPBSficBeb4i3sdasbfwxP7J9uvl6dwONiVp70fw9dp5OfdxR5GH4 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEB5BQaIXXoUSnoOEuBlSe-3Y3AoiKiLkFKC31T7GJRKxo8RFqsSPZ2b9oCBVPcA1sR3vZHbnm9c3AC-cZSOYk40Sr1TE9tpHxgvvbZYxmKXSq5DB_zKbzOf58XFxvhdGyirFhy5boohwVsvmlmB0XxL3WjjS2DJKSCQeS0lOepDlV-FayrZWtHwx_TpkEiRx2PLtJVJ3qPounose84d9CjT-f5GYXgxFg0ma3vofi7kNNztAioetBt2BK1Tdhb3Dip3x1Rm-xFAiGmLve_Bz8W1Tr2y9rpfSKY18WtKanXY0J7Uw8G6RF4AMKXGoX8e6xHXLaIFL6UXh79qHuLNGRnctzRs0uKLGRKYjSEFeDP6mmMa2veYefJ6-X7w7irrxDZFTSdxEsU-ErJ8YkEgwKFcxOVWmRZlaX8YFq8TYSp5RMSRzCZnCZ7kzfP2EaOwYOt2Hnaqu6AFgahS7TpYFlDolXYFZ4cZlSiy3zPMxNQLV_2naddzmMmLjuz7oKVA7KWuRsu6kPIJXw22dKC674a1oxHCxcHOHD-rNie62ujYuJj9h5MVrVdYkNrXE-8GSZbDA3vQIivP6pJsQminbOSo6ueQFnvfKp_kckOSOqag-3WqGXkUsXcTZCPZbrRxekw_tnB3n4uE__PIzuHG0-DTTsw_zj49gN5bSHpmLM3kMO83mlJ7AdfejWW43T8P--wWElypm |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEB5BQYgLBcojlMciIW6G1F47NrcWiEBUUQ8BelvtY7ZEInaUuEiV-uOZWa_NQ6p6gKvjx-5kdvabnZlvAF5YQ5tgiSbJnJQJ7dcu0Y55b4uCwCx6J0ME_8vhZDYrj4-ro5hNuIlplexD-44oIthqXtwr5_uMuNdMkUYbI5-IpGPOyMn3ivIqXCPoXLD_NZ9-HQIJHDfs6PYyTjuUfRHPRa_5Y3sKLP5_cZhejETDjjTd_g9zuQ23IhwV-53-3IErWN-Fnf2aXPHlmXgpQoJoOHnfgfP5t3WzNM2qWXCdtCBbiSty2YU-aZh_dyNo_IIApRiy10XjxarjsxALrkSh37qX2LOWG3ct9BuhxRJbnehIjyJoLuIXwbToimvuwefp-_nbD0ls3pBYmaVtkrqMqfqR4AgfBZUyRSt9XvncOJ9WpBBjw1FGSYDMZqgrV5RW0_0TxLEl4HQftuqmxocgci3JcTIkoNxKrgksKjv2OZLcCkdGagSy_8-Ujczm3GDju9rrCVCjlBVLWUUpj-DV8FgUxWUPHLBCDDczM3e40KxPVFzoStsU3YRwF81VGp2Z3CCtBoOGoAL50iOoflcn1YaDGd91UVHZJQN43uueIivAoR1dY3O6UQS8qpRriIsRPOiUchgmmeyS3Obq0T98-RncOHo3VYcfZ5924WbKeT3cFGfyGLba9Sk-gev2R7vYrJ-G1fcT1MYpFw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombopoietin+receptor+agonists+for+the+treatment+of+primary+immune+thrombocytopenia%3A+a+meta-analysis+and+systematic+review&rft.jtitle=Platelets+%28Edinburgh%29&rft.au=Simone+Birocchi&rft.au=Gian+Marco+Podda&rft.au=Marco+Manzoni&rft.au=Giovanni+Casazza&rft.date=2021-02-17&rft.pub=Taylor+%26+Francis+Group&rft.issn=0953-7104&rft.eissn=1369-1635&rft.volume=32&rft.issue=2&rft.spage=216&rft.epage=226&rft_id=info:doi/10.1080%2F09537104.2020.1745168&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ac2ed7782f594ba3b5be938beb362094 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0953-7104&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0953-7104&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0953-7104&client=summon |